The strongest honest case for compounded GLP-1s usually goes like this:

"The molecule is the same. Reputable compounders test their finished vials. I know where mine comes from."

That argument has a specific failure mode. FDA inspectors documented it in August and September 2026.

What FDA Inspectors Actually Found

Using documents obtained through a Freedom of Information Act request, Bloomberg reported on October 15, 2026 what US FDA inspectors documented at two Chinese factories making active pharmaceutical ingredients (API) for compounded GLP-1 drugs.

At Chengdu Shengnuo Biopharm Co. (Chengdu Shengnuo Biotec subsidiary), inspectors observed:

Black mold on equipment
"Gross contamination" on floors
Insects in ceiling voids
Workers hiding paperwork and pouring out product samples while inspectors were on site; inspectors could not recover all of the documents

At Nanjing Chengong Pharmaceutical Co., a September inspection found:

Employees buying active ingredient made at other factories and releasing it under Nanjing Chengong's own certification

Both companies made semaglutide and tirzepatide API — the active pharmaceutical ingredients used in compounding pharmacies to produce the finished injectable products sold to patients.

Both companies are now on the FDA import-alert list. Their products can be seized at the US border.

Source: Bloomberg, October 15, 2026 (FOIA inspection documents). Also reported by Quartz and NewsNation.

Why Finished-Vial Testing Can't Catch This

The most important thing to understand about this finding is where in the supply chain it sits.

The supply chain for a compounded GLP-1 looks like this:

API manufacturer (China) → synthesizes the raw peptide molecule
API supplier/distributor → ships to the US
Compounding pharmacy → formulates, sterility tests, and ships finished vials
Patient → receives and injects

The FDA inspection documented problems at Step 1.

When a compounder tests their finished vials, they're testing the product at Step 3. They rely on documentation — certificates of analysis, quality control records — from Steps 1 and 2 to know whether the raw material they used was what it claimed to be.

If the quality control records at the API plant are falsified, the compounder is testing their finished vial against documentation that may not reflect what was actually manufactured.

You can pass the finished-vial test and still have no reliable information about:

Whether the API contained the correct peptide at the stated concentration
Whether the API contained uncharacterized impurities
Whether the manufacturing conditions were controlled
What the endotoxin burden was in the raw material

The 2026 glutathione recalls show the same dependency from another angle. Several pharmacies recalled injectable glutathione for elevated endotoxin. FDA traced glutathione compounded by different pharmacies to a single supplier lot, and the agency had already warned in 2019 against using dietary-supplement-grade glutathione in injectable products.

This Is a Regulator's Own Finding — Not an Advocacy Claim

It's worth being explicit about what type of evidence this is, because the source matters.

This is not:

A FAERS adverse-event report (voluntary, unverified, no denominator)
A manufacturer's press release
A news outlet's characterization of secondhand information

This is FDA inspectors directly observing and documenting conditions at manufacturing facilities, findings obtained through the FOIA process. It is a regulator's own inspection record.

The Specific Problem Falsified Records Create

Here's the scenario in concrete terms:

A compounder receives a shipment of semaglutide API from a Chinese supplier, along with a certificate of analysis showing the material meets pharmaceutical specifications: correct identity, potency within range, endotoxin below threshold, impurities within limits.

The compounder formulates the finished product, runs their own sterility and endotoxin testing, and the vials pass.

But suppose the API manufacturer's internal QC records — the kind of records inspectors found being hidden — don't reflect what actually went through the manufacturing process, and the certificate of analysis shows acceptable numbers regardless of what was measured.

Then the compounder has tested their product against a fiction.

What "Pharmaceutical-Grade API" Actually Means

Not all API is the same. There's a meaningful distinction:

Research-grade or supplement-grade API: Synthesized to a basic purity standard, often intended for laboratory use. May not undergo the full suite of pharmaceutical testing. Often cheaper.

Pharmaceutical-grade API from a GMP-certified manufacturer: Manufactured under Good Manufacturing Practice regulations, with documented process controls, batch records, and quality systems subject to regulatory inspection. More expensive. Subject to the same inspection standards that produced these findings — which means the inspection process itself is the accountability mechanism.

The problem with falsified records is that it exploits the gap between what GMP certification claims and what the facility actually does. An import-alert listing closes that gap for those specific facilities — but only after inspection.

The Pattern This Year

This is not the first compounding quality failure involving the API layer in 2026:

Victory Medical Center Pharmacy: recalled compounded glutathione for elevated endotoxin
Optimal Balance Pharmacy: recalled compounded glutathione multi-dose vials for elevated endotoxin
Centric Compounding (Houston, TX): recalled glutathione and two other injectables on September 9, 2026, after nine adverse-event reports
Greenwich Rx (Tomball, TX): recalled glutathione on October 1, 2026; two patients needed emergency care after IV administration of a product not formulated for IV use
Two Chinese GLP-1 API plants: placed on import alert after FDA inspections in August and September 2026

The causes are not identical — the Greenwich reports also involved a product given by the wrong route. What the cases share is that a finished-product test is only as good as what came in the door.

What to Ask Before Injecting Anything Compounded

These questions cannot be answered by a certificate of analysis from an unknown supplier:

Where does the API come from? Which specific manufacturer? Is that manufacturer on the FDA import-alert list?
What is that manufacturer's inspection history? Has it been inspected by FDA or an equivalent authority? What were the findings?
What testing does the compounding pharmacy perform on the raw material, beyond relying on the supplier's certificate of analysis?
Has the pharmacy independently tested for endotoxin, identity, and potency — not just accepted the supplier's documentation?
What happens if a problem is identified? What is the recall and adverse-event reporting process?

A licensed 503A pharmacy operating in good faith should be able to answer these questions. A gray-market vendor cannot.

Sources

Bloomberg (Anna Edney), "Black Mold, Bugs Found at Chinese Plants Making GLP-1 Compounding Agents," October 15, 2026. FOIA documents confirmed.
Quartz, "FDA found black mold and bogus records at 2 Chinese suppliers of weight loss drug ingredients," October 15, 2026.
NewsNation, "FDA finds mold at Chinese factories making compounded GLP-1 drugs: Report," October 16, 2026.
FDA, Centric Compounding nationwide recall of glutathione, Myer's Cocktail and Tri-Immune Boost, September 9, 2026.
FDA MedWatch, Greenwich Rx recall, October 1, 2026. fda.gov confirmed.

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical or legal advice. Consult a licensed healthcare provider and pharmacist before using any compounded medication.

Black Mold, Falsified Records, and Why 'I Get Mine Tested' Doesn't Solve This